NCT03167203View on ClinicalTrials.gov

A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Macular Degenerative Disease
Interventions
BIOLOGICAL

Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial

Trial Locations (2)

64133

Private Practice, Kansas City

Unknown

Site GB44001, London

All Listed Sponsors
lead

Astellas Institute for Regenerative Medicine

INDUSTRY